Xencor (NASDAQ:XNCR): Strong Trend, Weak Setup
Early Arthritis Data Could Be A Big Test For Xencor Stock (XNCR)
Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657
Cantor Fitzgerald Reiterates Overweight on Xencor, Maintains $70 Price Target
Xencor (XNCR) Stock Trades At A Premium To Its Sales
Xencor: Q3 Earnings Snapshot
Xencor Reports Third Quarter 2026 Financial Results
Xencor Q3 EPS $0.50 Beats $(0.73) Estimate, Sales $116.520M Beat $78.587M Estimate
Xencor Sees Upside Potential After 'Exciting' Kidney Cancer Trial Data, RBC Capital Markets Says
Truist Securities Maintains Buy on Xencor, Raises Price Target to $40
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $43
Wells Fargo Maintains Overweight on Xencor, Raises Price Target to $44
Wedbush Maintains Outperform on Xencor, Raises Price Target to $45
Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma - Slideshow
Xencor (XNCR) Is Up 15.8% What's Changed After Kidney Cancer Trial Update
Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
Xencor Soars 31% on Kidney Cancer Trial Data Showing “Impressive Antitumor Activity”
Xencor shares jump as kidney cancer drug data support Phase 3 plans
Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.